Clinical trial
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or…
NCT00483262 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00483262 |
|---|---|
| Title | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma |
| Official title | Phase I/II Trial of Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry Millennium Pharmaceuticals, Inc. |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CCI-779, Bortezomib |
| Enrollment | 63 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2011 |
| Completion | Feb 1, 2012 |
| First posted | Jun 6, 2007 |
| Last update posted | Nov 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: